Ansana

End-to-end Management of your Sterilization Processes




Ansana's **mission** is to improve patient safety, and to make healthcare more sustainable and affordable

Ansana's vision is to become the standard in sterilization process management and control in healthcare



Every year **310 million surgeries** are performed globally, requiring >1 billion sterile surgical instrument sets. Guaranteeing service levels to the Operating Room becomes increasingly challenging



Patient risk

- Surgical Site Infections (SSIs) affect yearly > 3 million patients in Europe and USA
- Studies allocate **22%** of SSIs to surgical instrument reprocessing

Process & labor


- Hospitals and medical device companies carry huge inventory of surgical Instruments⁴
- ▲ Operating Room service disruptions generate very high costs⁵
- Challenge to identify, train & retain talent


Waste & carbon footprint

A Only in the USA, every year 115 mio kg plastic waste is generated because of consumables used in sterilization processes³

Ansana

Ansana's solution manages the end-to-end reprocessing flow, thereby guaranteeing instrument sterility, eliminating consumables, and optimizing the process





Smart device





- K Real-time Location Tracking
- Frocess Parameter Measurement
- ▲ Data exchange, capture & processing



Ansana is ...



Smart Device

- Real-time location tracking
- Process parameter measurement
- A Data exchange



Data Modules

- A Quality release
- Flanning & scheduling
- **A** OR service management
- Inventory optimization
- Capacity bottleneck management
- Human resource management
- κ...



Services

- A Process optimization projects
- K Technology implementation

- Real-time monitoring & trouble shooting
- Fredictive maintenance & continuous optimization

Ansana's unique value proposition brings solutions to the key problem owners in hospitals

Ansana's main benefits



Patient Safety Surgical Site Infection reduction




Cost Efficiency Operating Room service improvement Surgical instrument inventory reduction Capacity increase




Sustainability

Elimination of consumables Sterilization cycle optimization




Ansana demonstrates a strong interest from potential customers and exit candidates





Ansana will initially target the **Healthcare Facilities** market of € 2.2 bn



Ansana's go-to-market strategy assures fast access and adoption



Marketing & Access

- Specialized conferences
- **K** Establish **collaborations**
- Implement Pilot
 Projects in EU & US



Commercial

- Direct sales for pilot & early projects
- Sales / distribution partnerships for scalability
- Service partnerships



Regulatory

- ISO 13485 Quality Management System
- Regulatory Clearance for class II device in US & EU




IP

 Exclusive license on global portfolio of 38 patents by Stryker Corporation




Ansana can rely on an experienced team and efficient partnerships







Ansana is looking to raise \in 12 M, of which \in 6 M in equity, in order to bring the company to profitability





Ansana's financials forecast a fast path to revenue & profitability





Healthcare Ambulant Total



Investment highlights



Large and Growing Market

 $\textcircled{\mbox{\sc c}}$ 2,2 B total addressable market with a CAGR of 10,5%, plus potential for additional markets



Competitive Advantage

Unique and patented solution for the full flow, outperforming competition in every aspect



Strong IP Protection

Global patent portfolio with an open patent family in every major geography



Scalable Business Model with strong Finance KPI's

€ 55,4 M revenue and € 19,6 M EBITDA 5 years after market launch, with potential for fast growth



Experienced Team & Strong Partnerships

Experienced Management Team, Advisory Board with all required competencies, efficient partners



Excellent Exit Potential

Strong corporate interest and collaboration

Investment opportunity

- Ansana is currently approaching potential investors for a total investment of €1.500 K in equity funding
- The seed round secures sufficient funding for the testing at partner hospitals in the EU and US, for the development of a Min imal Viable Product, and for ISO 13485 certification
- Currently € 1.000 K is committed



Thank You

Dominique Surinx CEO & Co-Founder Telephone: +32 479 999 809 E-mail: <u>dominique.surinx@ansana.health</u> Website: <u>https://ansana.health</u>

